Safety and Efficacy of Two Once Daily Anti Retroviral Treatment Regimens Along With Anti-tuberculosis Treatment

NCT00332306 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

180

Enrollment

OTHER_GOV

Sponsor class

Conditions

Tuberculosis
Human Immunodeficiency Virus Infections

Interventions

DRUG: Didanosine, Lamivudine, Efavirenz
DRUG: Didanosine, Lamivudine, Nevirapine

Sponsor

Tuberculosis Research Centre, India

Collaborators

[object Object]
[object Object]